Abstract: Provided is a method of manufacturing a server room cooling apparatus, the method including: providing a housing; providing at least one frame in the housing; providing, on the at least one frame, a barrier wall configured to divide a space inside the housing into at least two spaces; forming a mist ejection unit configured to eject mist to an outer air supplied from outside the server room cooling apparatus, at a side of a supply unit that is formed by the barrier wall and supplies outer air to a server room; forming a filter unit configured to filter outer air supplied from outside the server room cooling apparatus, at a side of the mist ejection unit; and forming an outer air inflow unit into which outer air flows, at one side of the filter unit.

Abstract: Provided is a server room cooling device including: an outer air inflow unit into which outer air flows; a filter unit provided at one side of the outer air inflow unit and filtering the outer air supplied through the outer air inflow unit; a mist ejection unit provided at one side of the filter unit and ejecting mist into the outer air that has passed through the filter unit; and a supply unit provided at one side of the mist ejection unit and supplying the outer air that has passed through the mist ejection unit to a server room.

Abstract: A more efficient power supply unit and a method for supplying power using same are disclosed. The power supply unit comprises a relay for switching alternating current power supplied from a plurality of sources; a direct current power supply for converting the switched current power to direct current power; and a controller for generating a switch signal to control the relay to switch the sources on the basis of the result for monitoring the alternating current power supplied from the sources.

Abstract: The present invention provides a novel 2-pyridyl substituted imidazole derivative, or a pharmaceutically acceptable salt or solvate thereof, which selectively inhibits the transforming growth factor-? (TGF-?) type I receptor (ALK5) and/or the activin type I receptor (ALK4); a pharmaceutical composition comprising same as an active ingredient; and a use of the 2-pyridyl substituted imidazole derivative for the manufacture of a medicament for preventing or treating a disease mediated by ALK5 and/or ALK4 receptors in a mammal.

Abstract: A more efficient power supply unit and a method for supplying power using same are disclosed. The power supply unit comprises a relay for switching alternating current power supplied from a plurality of sources; a direct current power supply for converting the switched current power to direct current power; and a controller for generating a switch signal to control the relay to switch the sources on the basis of the result for monitoring the alternating current power supplied from the sources.

Abstract: A more efficient power supply unit and a method for supplying power using same are disclosed. The power supply unit comprises a relay for switching alternating current power supplied from a plurality of sources; a direct current power supply for converting the switched current power to direct current power; and a controller for generating a switch signal to control the relay to switch the sources on the basis of the result for monitoring the alternating current power supplied from the sources.

Abstract: The present invention relates to a composition comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl]-2-thiophene carboxyamide as an active ingredient, manufactured by a melt extrusion method. The composition according to the present invention has a wide variety of advantages such as securing dissolution rate and bioavailability of the active ingredient, improving absorption deviation depending on whether a patient has a meal or not, and securing stability during the manufacturing process. The present invention further provides a method which can manufacture the said composition.

Abstract: Provided is a method of manufacturing a server room cooling apparatus, the method including: providing a housing; providing at least one frame in the housing; providing, on the at least one frame, a barrier wall configured to divide a space inside the housing into at least two spaces; forming a mist ejection unit configured to eject mist to an outer air supplied from outside the server room cooling apparatus, at a side of a supply unit that is formed by the barrier wall and supplies outer air to a server room; forming a filter unit configured to filter outer air supplied from outside the server room cooling apparatus, at a side of the mist ejection unit; and forming an outer air inflow unit into which outer air flows, at one side of the filter unit.

Abstract: A method of operating a timing controller, which communicates with a host through a mobile industry processor interface (MIPI) and communicates with a display panel module through a display interface, is provided. The method includes storing image data compressed by one of the host and the timing controller in a frame memory, decompressing the image data stored in the frame memory, and performing panel self-refresh on the display panel module using the decompressed image data.

Abstract: Provided is a server room cooling device including: an outer air inflow unit into which outer air flows; a filter unit provided at one side of the outer air inflow unit and filtering the outer air supplied through the outer air inflow unit; a mist ejection unit provided at one side of the filter unit and ejecting mist into the outer air that has passed through the filter unit; and a supply unit provided at one side of the mist ejection unit and supplying the outer air that has passed through the mist ejection unit to a server room.

Abstract: Disclosed is a composition effective in reducing skin wrinkles. The composition comprises a phosphodiesterase 5 (PDE5) inhibitor, preferably the compound of chemical formula 1, more preferably, mirodenafil as an active ingredient. Further disclosed is a method for reducing skin wrinkles using the composition.

Abstract: The present invention relates to an extract isolated from Sophorae Radix useful for prevention and treatment of respiratory diseases. More specifically, the present invention relates to a pharmaceutical drug comprising the Sophorae Radix extract having excellent effects of inhibiting airway contraction, respiratory infections, 5-lipoxygenase activity, phosphodiesterase 4 activity, airway hyper-responsiveness and airway remodeling; antagonistic activity against leukotriene D4; and an antitussive effect, thus being useful for prevention and treatment of respiratory diseases such as asthma, acute or chronic bronchitis, allergic rhinitis, acute upper respiratory infections and acute lower respiratory infections, and the like.

Abstract: The present invention relates to a pharmaceutical or cosmetic composition and a method for promoting eyelash growth, wherein nipradilol or pharmaceutically or cosmetically acceptable salts thereof are used as active ingredients. The composition of the invention may comprise prostaglandin F2? analogs.

Abstract: Disclosed is a composition effective in reducing skin wrinkles. The composition comprises or uses a phosphodiesterase 5 (PDE5) inhibitor as an active ingredient. Further disclosed is a method for reducing skin wrinkles using the composition.

Abstract: Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11?-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11?-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human-derived 11?-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LADA), insulin tolerance syndromes, obesity, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.

Abstract: A method of operating a timing controller, which communicates with a host through a mobile industry processor interface (MIPI) and communicates with a display panel module through a display interface, is provided. The method includes storing image data compressed by one of the host and the timing controller in a frame memory, decompressing the image data stored in the frame memory, and performing panel self-refresh on the display panel module using the decompressed image data.

Abstract: A more efficient power supply unit and a method for supplying power using same are disclosed. The power supply unit comprises a relay for switching alternating current power supplied from a plurality of sources; a direct current power supply for converting the switched current power to direct current power; and a controller for generating a switch signal to control the relay to switch the sources on the basis of the result for monitoring the alternating current power supplied from the sources.

Abstract: The present invention provides a compound of formula (I) or a prodrug thereof useful for treating or preventing irritable bowel syndrome, and a composition comprising the compound as an active ingredient. Also, the present invention provides a method for treating or preventing irritable bowel syndrome, which comprises administrating a therapeutically or prophylactically effective amount of the compound or the composition to a subject in need of treating or preventing irritable bowel syndrome.

Abstract: The present invention relates to a pharmaceutical or cosmetic composition and a method for promoting eyelash growth, wherein nipradilol or pharmaceutically or cosmetically acceptable salts thereof are used as active ingredients. The composition of the invention may comprise prostaglandin F2? analogues.

Abstract: Disclosed is a composition effective in reducing skin wrinkles. The composition comprises a phosphodiesterase 5 (PDE5) inhibitor, preferably the compound of chemical formula 1, more preferably, mirodenafil as an active ingredient. Further disclosed is a method for reducing skin wrinkles using the composition.